Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2014203188) ASSAY FOR COMPLEMENT FACTOR I (CFI) BIOACTIVITY
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/203188 International Application No.: PCT/IB2014/062384
Publication Date: 24.12.2014 International Filing Date: 18.06.2014
IPC:
G01N 33/68 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
Applicants:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED [GB/GB]; 980 Great West Road Brentford Middlesex TW89GS, GB
Inventors:
LOPEZ, Francisco; US
Priority Data:
61/836,76419.06.2013US
Title (EN) ASSAY FOR COMPLEMENT FACTOR I (CFI) BIOACTIVITY
(FR) NOUVEAU DOSAGE
Abstract:
(EN) The present invention relates to a CFI bioactivity assay designed to quantitatively measure (a) CFI bioactivity of plasma or other body fluids; and (b) bioactivity of CFI in plasma or other body fluids of a human patient afflicted by a disease that involves amyloid deposition in tissues, in particular Alzheimer disease, AMD, glaucoma, or beta-amyloid cataract formation.
(FR) La présente invention concerne un dosage de la bioactivité du CFI conçu pour quantitativement mesurer (a) la bioactivité du CFI du plasma ou autres fluides biologiques; et (b) la bioactivité du CFI dans le plasma ou autres fluides biologiques d'un patient humain souffrant d'une maladie qui implique un dépôt amyloïde dans les tissus, notamment la maladie d'Alzheimer, la DMLA, le glaucome, ou la formation de cataracte causée par la bêta-amyloïde.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)